Founded Year

2017

Stage

Series D | Alive

Total Raised

$247.65M

Valuation

$0000 

Last Raised

$108.09M | 1 yr ago

About Shukun Technology

Shukun Technology develops diagnostic systems by using machine learning and AI technology for hospitals to improve efficiency. The company focuses on cardiovascular diagnosis.

Shukun Technology Headquarters Location

Room 801, Jinhui Building, Qiyang Road, Chaoyang District

Beijing, Beijing,

China

+86-10-89735152

ESPs containing Shukun Technology

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Medical Devices Tech

Computer-aided diagnostic imaging utilizes algorithms to detect, extract, and communicate data from medical images more efficiently and accurately than the human eye. The technology is being deployed across several imaging modalities to improve the detection, diagnosis, triaging, and, ultimately, the prognosis of various medical conditions.

Shukun Technology named as Leader among 14 other companies, including PathAI, Ibex Medical Analytics, and Aidoc Medical.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Shukun Technology's Products & Differentiation

See Shukun Technology's products and how their products differentiate from alternatives and competitors

  • digital body

    digital body

Research containing Shukun Technology

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Shukun Technology in 2 CB Insights research briefs, most recently on Sep 3, 2020.

Expert Collections containing Shukun Technology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Shukun Technology is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,180 items

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health

13,551 items

M

Medical Devices

8,694 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Hospital

198 items

Startups recreating how healthcare is delivered

Latest Shukun Technology News

China tech last year: Medical AI industry aims for commercialization, exploring new possibilities

Dec 29, 2021

China tech last year: Medical AI industry aims for commercialization, exploring new possibilities MedTech firms are speeding up their efforts to better connect AI technology with the demand side. SHARE In China, medical AI is advancing rapidly, but profitability remains a crucial problem common in the industry. Medtech companies, even leading players such as Airdoc, Keya Medical, Infervision and Shukun Technology, have yet to achieve profitability as research and development costs remain high. Their annual losses range from tens of millions of yuan to hundreds of millions of yuan. Commercialization has become the top priority for medtech companies. Therefore, they are making the effort to better connect innovative applications with the demand side. AI for Digital Therapeutics(DTx) According to “Medtech leaders prioritize technology and consumers” , a report by Deloitte, 63% of medtech companies surveyed agreed that Digital Therapeutics(DTx) will have a major impact on the industry over the next 10 years. Meanwhile, according to the predictions of Insider Intelligence, the DTx market will reach $9 billion in 2025 and $56 billion by 2035. Digital Therapeutics are therapeutic methods focused on delivering clinical outcomes with the aid of digital technology such as wellness apps, wearables, and interactive simulations. One of the med-tech companies in China focusing on DTx is Beijing-based WM Therapeutics. Founded in 2010, WM Therapeutics focuses on the integration of neurocognitive science, clinical medicine, and computer science. WM Therapeutics has visited nearly 100 psychiatric and neurological clinical departments and developed an AI digital health care solution for CNS(central nervous system disease) disease that integrates the entire process of screening, diagnosis, and treatment, to treat diseases such as Alzheimer, according to Gao Yan, CEO of WM Therapeutics at an industry conference. WM Therapeutics’s AI digital medical solution for CNS disease can accurately diagnose the cognitive function of patients with machine learning methods, identify the damage of individual brain networks with AI data analysis, thus providing patients with more accurate personalized treatment plans and patient behavior management. The AI DTx solution can also accurately analyze the behavior of patients after taking certain medications, therefore personalizing the management of side effects of medications, improving the efficacy of medication, and treating CNS disease more effectively. By the end of 2021, WM Therapeutics has cooperated with more than 10 top medical facilities in the field of neuropsychiatry in China, applying the DTx method clinically. AI for drug development From preliminary research to clinical trials, monitoring, and regulator’s review, a new drug can take ten years on average to develop, costing $2.8 billion during the process. Over the last few years, AI technology has shown it has the potential to revolutionize the drug development scenario to a much more time-efficient and less costly one. According to Bekryl Market Analysts , AI has the potential to provide over US$70 billion in savings for the drug discovery process by 2028. There are approximately 138 AI drug development startups worldwide, with the US in the lead, having 86 in total, according to CB Insights. China’s tech companies are late to the game. According to statistics provided by Huoshi Database, there are currently less than 20 AI drug development startups in China, mainly located in Beijing, Shanghai, Hangzhou, and Shenzhen. Big tech companies in China have shown a growing interest in the industry for the past year. Baidu launched BioMap in late 2020. BioMap is a biotech company focusing on innovative approaches in drug development, with Baidu’s founder Yanhong Robin Li as CEO. At the beginning of 2021, BioMap launched a recruitment plan , aiming to attract people with medtech and AI backgrounds with a $1 million annual salary. The move shows Baidu is optimistic about the future of the medical AI industry. In mid-2021, BioMap completed its Round A financing , raising hundreds of millions of dollars. The financing was led by GGV Capital and followed by Baidu, Legend Capital, BlueRun Ventures, Verity Ventures, and Xianghe Capital. According to information released at Creator 2021, Baidu’s annual industry conference, BioMap has used its biocomputing platform and large-scale pre-trained models to successfully shorten the prediction time of typical protein structures from the current industry benchmark of 30 minutes to less than 5 minutes. Previously, ByteDance and Huawei both started recruiting for biomedical-related positions. ByteDance launched Weihe, a medical laboratory company on December 29, while Tencent released its first AI-driven drug development platform, iDrug. AI for medical imaging 90% of all healthcare data comes from medical imaging--and more than 97% of it is not analyzed or used, according to findings by GE Healthcare . AI medical imaging can offer a more efficient and accurate way of providing such medical services. According to a report by Signify Research, the world market for machine learning in medical imaging, comprising software for automated detection, quantification, decision support, and diagnosis, is forecast to top $2 billion by 2023. Chinese medtech companies such as Airdoc, Keya Medical, Shukun Technology, and Infervision have been focusing on the AI application in medical imaging and achieving key accomplishments in 2021. Following COVID-19, medtech companies in China have been collaborating with hospitals to develop AI imaging methods and systems for COVID-19 and other cases of pneumonia. Shukun Technology, Infervision and Deepwise, three Beijing-based medical startups have respectively gotten license approvals for their AI pneumonia diagnosis products in 2021. Around April 2021, Infervision and Deepwise respectively received Class III licenses from Chinese regulators. A prototype of Infervision’s AI pneumonia diagnosis product has been used by Wuhan Tongji Hospital since the beginning of the pandemic in China, while Deepwise’s product has been used by Wuhan Ninth Hospital and Huoshenshan Hospital. AI pneumonia diagnosis products have also been embraced by hospitals in Japan, Italy, Germany and other countries and regions. On April 1, 2021, Infervision announced that the EU government has decided to purchase the AI COVID screening and diagnosis system from the company for the second time. Shukun Technology got its Class III license for its AI pneumonia diagnosis product in December 2021. According to Shukun Technology, it has completed a retrospective clinical trial in China to validate the diagnostic performance of its pneumonia diagnosis AI. The study included a total of 812 chest CT scans from multiple medical centers, including 273 CT scans of COVID-19 cases and 539 CT scans of non-pneumonia abnormalities. Shukun’s AI diagnosis system came back with excellent performance in key evaluation metrics. Prior to receiving the Class III license in China, Shukun Technology has also received CE certificates of EU Medical Device Regulation (MDR) for its AI pneumonia diagnosis system in May, 2021. AI for surgical robots Compared to traditional surgery, surgical robots can offer more precision, minimize wound sizes and pain, also reduce the time needed for recovery. According to iResearch, the market size of surgical robots in China was 2.7 billion yuan in 2020, and is expected to grow rapidly and reach 19.3 billion yuan by 2025. AI-powered surgical robots industry embraced a boom in 2021, as favorable regulations encourage the development and application of such technology. In February 2021, China’s Ministry of Industry and Information Technology released a draft of the "Medical Equipment Industry Development Plan (2021-2025)" for public comment, in which surgical robots were identified as a key development area, and development plans were made for all technologies related to surgical robots. The plan also proposed to include surgical robots and related medical services in China’s national medical insurance. Subsequently, Shanghai and Beijing issued relevant policies. Shanghai announced in April that da Vinci surgical robots by American company Intuitive Surgical will be included in medical insurance, but will only be limited to four kinds of surgical procedures — radical prostatectomy, partial nephrectomy, total hysterectomy, and radical rectal cancer. Beijing announced in August that surgical robots by Chinese medtech company Tinavi will be included in the medical insurance. The move solved a major obstacle to the application of surgical robots. Expensive pricing has long been a critical reason limiting the widespread use of surgical robots. Cover image by Testalize.me on Unsplash.

Shukun Technology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Shukun Technology Rank

  • When was Shukun Technology founded?

    Shukun Technology was founded in 2017.

  • Where is Shukun Technology's headquarters?

    Shukun Technology's headquarters is located at Room 801, Jinhui Building, Qiyang Road, Chaoyang District, Beijing.

  • What is Shukun Technology's latest funding round?

    Shukun Technology's latest funding round is Series D.

  • How much did Shukun Technology raise?

    Shukun Technology raised a total of $247.65M.

  • Who are the investors of Shukun Technology?

    Investors of Shukun Technology include Marathon Venture Partners, Sequoia Capital China, Primavera Capital Group, Jane Street Group, Weilai Qichuang Fund and 16 more.

  • Who are Shukun Technology's competitors?

    Competitors of Shukun Technology include Koios Medical, Cleerly, Lunit, Aidoc Medical, Viz.ai, SenseTime, Overjet, Iterative Scopes, Aiforia, Shenzhi Technology and 29 more.

  • What products does Shukun Technology offer?

    Shukun Technology's products include digital body.

You May Also Like

A
Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Ultromics Logo
Ultromics

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

R
RadNet

RadNet is a national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. The company has a network of 293 owned and/or operated outpatient imaging centers.

RapidAI Logo
RapidAI

RapidAI is using AI to combat life-threatening vascular and neurovascular conditions. From home to hospital and ER to OR, RapidAI is leading the next evolution of clinical decision-making and patient workflow, bringing the end-to-end patient journey into focus.

ScreenPoint Medical Logo
ScreenPoint Medical

ScreenPoint Medical, based in Nijmegen, has developed smart software for improving results of breast cancer screening. This software reads mammograms like a human reader and supports radiologists by identifying and interpreting potential problem areas on x-ray images. This reduces the chance of missing tumors and may be used to organize screening more efficiently.

Perspectum Logo
Perspectum

Perspectum is a provider of digital technologies that help clinicians provide better care for patients with liver disease. The company's work focuses on the detection and accurate, quantitative measurement of liver, gall bladder, and pacreatic disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.